In our patient, after the initiation of antineoplastic chemotherapy, a precipitous fall in the serum lactate concentration occurred, accompanied by the restoration of a normal L/P ratio and correction of metabolic acidosis (Fig. 1). Rapid involution of Hodgkin’s disease occurred simultaneously, evidenced by complete disappearance of the parotid swellings and submandibular lymphadenopathy and a marked diminution in the liver size. This therapeutic response suggests that the lactic acidosis could be attributed directly to the Hodgkin’s disease.

Although administration of massive amounts of intravenous bicarbonate may be imperative in the initial treatment of patients with severe lactic acidosis, this therapy is not without hazards since lethal hyperosmolality has been observed. In addition, recent studies in animals have also provided evidence suggesting detrimental effects of bicarbonate in the treatment of experimentally induced lactic acidosis.

The evidence reported here suggests that when lactic acidosis is associated with Hodgkin’s disease, the successful reversal of this potentially lethal metabolic derangement may depend on the prudent institution of effective antineoplastic chemotherapy rather than on bicarbonate administration alone. Chemotherapy may have importance in the treatment of patients with lactic acidosis in other neoplasms that are susceptible to specific therapy.

REFERENCES
ed for American girls. Probit analysis could not be used to estimate the mean age of the whole group because of the high percentage of older dancers reporting "no menarche yet"; the data therefore did not conform to a sigmoid curve.

Dancers with amenorrhea and with irregular cycles were significantly leaner than dancers reporting regular cycles (Table 1). The 20 dancers of all ages reporting "no menarche yet" were significantly leaner than the dancers of the three other groups (F = 7.69, P<0.01). As is indicated by their average total body water as per cent of body weight, the weight for height of each of these dancers was below the critical weight for height necessary for menarche or the maintenance of regular cycles in well-nourished women with average activity. Their weights for height are also below the standard termed "underweight" for young women. Even the dancers in the group with regular cycles also were in the very low range of weight for height and relative fatness for their age; however, all but one of them were above the threshold, minimum weights for menarche or maintenance of cycles. Two dancers reporting irregular cycles were in the range of normal fatness for maintaining cycles, demonstrating that the weight is necessary but not sufficient for cycles to occur; emotional or physical stress may override the effect of weight.

The mean height (158.7 ± 1.2 cm) of the 11 dancers reporting "no menarche yet" at a mean age of 14.3 ± 0.4 years (Table 1) was similar to the height (158.5 ± 0.5 cm) of well-nourished non-dancers at menarche at 12.9 ± 0.1 years, but the mean weight of the dancers (42.0 ± 0.9 kg) was significantly less than that of the well-fed girls (47.8 ± 0.5 kg) (P<0.001).7

**DISCUSSION**

The relatively late mean age at menarche and the delayed menarche of the dancers may show that late maturers choose to be ballet dancers or that the hard training and low food intake typical of ballet dancers cause excessive thinness that delays puberty.3 The fact that most of the dancers began their training at young ages (Table 1), and the high incidence of secondary amenorrhea and irregular cycles suggest that the latter factors — hard training and low intake — contribute strongly to this phenomenon.

Warren has reported a late mean age of menarche, 15.4 years, for 13 selected young ballet dancers, in association with thinness and the energy drain of hard training.9 A sample group of women runners also had a relatively late age at menarche and a high incidence of amenorrhea, the latter positively correlated with the number of miles run per week.10 Finally, high school and college athletes have a statistically significant later age at menarche than do nonathletes.11

The occurrence of menarche after an injury preventing dancing supports the hypothesis that a change in fat/lean ratio and the accompanying changes in metabolic and hormonal levels characteristic of hard physical exercise may be involved in the delay of menarche and menstrual disturbances in these ballet dancers. A change in the ratio may also result from an increase in leanness, in addition to a decrease in fatness, without weight loss or even with weight gain, as found in many athletes (Frisch RE, Welbergen A, McArthur JW, Albright T, Bullen B, Witschi J, Reed RB: unpublished data).14

We are indebted to E. L. Lowenkopf, M.D., for his assistance in collecting the data.

**REFERENCES**

3. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of

---

**Table 1. Characteristics of 89 Ballet Dancers Reporting Lack of Menstrual Cycles, Irregular Cycles, and Regular Cycles.**

<table>
<thead>
<tr>
<th>Group Classification</th>
<th>Age at Time of Study</th>
<th>Age at Menarche</th>
<th>Age at Start of Training</th>
<th>Height (cm)</th>
<th>Weight (kg/lb)</th>
<th>Estimated TW/BW*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary amenorrhea —</td>
<td>18.4 ± 0.5</td>
<td>Not Yet</td>
<td>8.4 ± 0.9</td>
<td>163.7 ± 1.3</td>
<td>43.5 ± 0.3</td>
<td>59.5 ± 0.6</td>
</tr>
<tr>
<td>age &gt; 16 (9)</td>
<td></td>
<td></td>
<td></td>
<td>(64.4 ± 0.5)</td>
<td>(95.7 ± 1.1)</td>
<td></td>
</tr>
<tr>
<td>No menarche yet —</td>
<td>14.3 ± 0.4</td>
<td>Not Yet</td>
<td>6.7 ± 0.5</td>
<td>158.7 ± 1.2</td>
<td>42.0 ± 0.9</td>
<td>58.9 ± 0.4</td>
</tr>
<tr>
<td>age &lt; 16 (11)</td>
<td></td>
<td></td>
<td></td>
<td>(62.5 ± 0.5)</td>
<td>(92.4 ± 2.0)</td>
<td></td>
</tr>
<tr>
<td>Secondary amenorrhea</td>
<td>17.9 ± 0.4</td>
<td>14.3 ± 0.4 $\dagger$</td>
<td>7.8 ± 0.4</td>
<td>162.7 ± 1.4</td>
<td>44.9 ± 1.6</td>
<td>58.3 ± 0.7 $\dagger$</td>
</tr>
<tr>
<td>(13)</td>
<td></td>
<td></td>
<td></td>
<td>(64.1 ± 0.6)</td>
<td>(98.8 ± 3.5)</td>
<td></td>
</tr>
<tr>
<td>Irregular cycles (27)</td>
<td>16.7 ± 0.3</td>
<td>13.9 ± 0.3 $\dagger|$</td>
<td>7.2 ± 0.7</td>
<td>163.5 ± 0.9</td>
<td>45.9 ± 0.7</td>
<td>57.7 ± 0.4 $\dagger$</td>
</tr>
<tr>
<td>(27)</td>
<td></td>
<td></td>
<td></td>
<td>(64.4 ± 0.4)</td>
<td>(101.0 ± 1.5)</td>
<td></td>
</tr>
<tr>
<td>Regular cycles (29)</td>
<td>17.0 ± 0.4</td>
<td>13.3 ± 0.2 $|$</td>
<td>7.4 ± 0.4</td>
<td>162.0 ± 1.0</td>
<td>47.0 ± 0.8</td>
<td>56.3 ± 0.5</td>
</tr>
<tr>
<td>(29)</td>
<td></td>
<td></td>
<td></td>
<td>(63.5 ± 0.4)</td>
<td>(103.4 ± 1.8)</td>
<td></td>
</tr>
<tr>
<td>All subjects (89)</td>
<td>16.8 ± 0.2</td>
<td></td>
<td>7.4 ± 0.3</td>
<td>162.3 ± 0.5</td>
<td>45.5 ± 0.5</td>
<td>57.6 ± 0.3</td>
</tr>
</tbody>
</table>

*Values are expressed as mean ± S.E.M.

$\dagger$Total body water expressed as percentage of body weight. Fat/body weight per cent = 100 - 4 per cent water

$\dagger$Significantly different from group with regular cycles, P<0.05.

$\dagger$Significantly different from group with irregular cycles, P<0.01.

$\dagger$Age for one subject was not known.


As the survival of patients with acute lymphoblastic leukemia has improved, increased attention has focused on the potential toxicity and adverse long-term sequelae of antileukemic therapy. In particular, there is considerable interest in the toxic effects on the central nervous system that may result from therapy to treat or prevent meningeval leukemia. A wide range of neurotoxicities have been described, the most serious of which is the syndrome of necrotizing leukencephalopathy associated with cranial irradiation and the administration of methotrexate. Clinically, patients with this delayed form of neurotoxicity present with symptoms such as poor performance in school, forgetfulness, and confusion.

From the Pediatric Oncology Branch, National Cancer Institute; the Department of Neurochemistry, Johns Hopkins University, Baltimore; and the departments of Pediatrics and Radiation Oncology, University of Washington, Seattle (address reprint requests to Dr. Gangji at 850, Room 3B-03, National Cancer Institute, Bethesda, MD 20205).

Dr. Gangji is a Fellow of the Rose et Jean Hoguet Cancer Research Foundation; Dr. Bleyer is a Scholar of the Leukemia Society of America; Dr. Cohen is a recipient of a grant (14167) from the National Institutes of Health.

LEUKOENCEPHALOPATHY AND ELEVATED LEVELS OF MYELIN BASIC PROTEIN IN THE CEREBROSPINAL FLUID OF PATIENTS WITH ACUTE LYMPHOBlastic LEUKEMIA

Diamon Gangji, M.D., Gregory H. Reaman, M.D., Stephen R. Cohen, Ph.D., W. Archie Bleyer, M.D., and David G. Poplack, M.D.

Frequently, however, they progress to a more serious clinical stage characterized by dysarthria, ataxia, seizures, dementia, or coma. The definitive diagnosis of this syndrome is usually established at autopsy by the histopathological finding in the brain tissue of demyelination accompanied by multifocal necrosis, astrocytosis, and occasionally dystrophic calcifications.

The cerebrospinal fluid of 39 patients who had acute lymphoblastic leukemia and had been treated with cranial irradiation and intrathecal methotrexate was examined for the presence of myelin basic protein, a specific component of the myelin sheath and an indicator of demyelination. Increased levels of this protein (>4 ng per milliliter) were detected in all seven patients with clinically overt necrotizing leukencephalopathy. Furthermore, serial determinations in two patients demonstrated that increasing levels of myelin basic protein in the cerebrospinal fluid correlated with disease progression and likewise returned to normal with resolution of clinical symptomatology.

METHODS

Patients

Cerebrospinal fluid was obtained from 39 patients who had acute lymphoblastic leukemia and were three to 20 years of age. The patients were categorized into four groups.

Group I consisted of seven patients with clinically overt signs and symptoms of necrotizing leukencephalopathy. All had received cranial irradiation (2400 rads) and multiple doses of intrathecal methotrexate for central-nervous-system prophylaxis. Two patients had received additional therapy for meningeal leukemia before the onset of leukencephalopathy. The diagnosis of leukencephalopathy was made on the basis of characteristic clinical findings and the exclusion of other possible causes of encephalopathy or demyelination.

Group II consisted of 21 patients who had previously completed central-nervous-system prophylaxis consisting of cranial irradiation (2400 rads) and multiple doses of intrathecal methotrexate. Cerebrospinal-fluid samples were obtained from one month to 6½ years after completion of central-nervous-system prophylaxis. Sixteen of the 21 patients were still receiving systemic maintenance chemotherapy without any intrathecal or intravenous methotrexate.

Group III consisted of seven patients undergoing central-nervous-system prophylaxis. Cerebrospinal fluid was obtained from these patients during the time of prophylactic treatment, which consisted of cranial irradiation and intrathecal methotrexate. All these patients were being treated with cranial irradiation and had received at least two doses of intrathecal methotrexate when samples of cerebrospinal fluid were obtained.

Group IV consisted of four patients with meningeal leukemia. These patients were receiving therapy for active meningeal leukemia when cerebrospinal-fluid samples were obtained. All four had received cranial irradiation and intrathecal methotrexate as prophylaxis and were being treated for meningeal leukemia with intralumbar or intraventricular methotrexate (two patients). All had a leukemic pleocytosis in the cerebrospinal fluid at the time of study.

Collection of Cerebrospinal Fluid

Cerebrospinal fluid (1 ml) was obtained from patients by lumbar puncture or Ommaya reservoir sampling either at the time of...